Journal of Clinical Pediatrics >
The survival predictive value of pre-treatment blood test indicators and risk factors for children with recurrent medulloblastoma
Received date: 2023-04-25
Online published: 2024-06-07
Objective To investigate the relationship between peripheral blood platelet-lymphocyte ratio, prognostic nutritional index and prognosis in patients with medulloblastoma (MB) after recurrence and before re-treatment. Methods A retrospective study was conducted on 82 patients with MB admitted from September 2015 to September 2022. The post-recurrence OS rates were compared between high/low neutrophil-lymphocyte ratio (NLR) group, high/low platele-lymphocyte ratio (PLR) group, high/low systemic inflammation index (SII) group, and high/low prognostic nutritional index (PNI) group, and the prognostic factors were analyzed. Results The critical values of NLR, PLR, SII and PNI were 3.1, 311.7, 763.7 and 49.0, respectively. Univariate analysis suggested that high NLR, high PLR, high SII and low PNI were associated with shorter OS rate, and the differences between groups were statistically significant (P<0.05). COX regression analysis suggested that PLR was an independent risk factor and PNI was a protective factor for OS after recurrence (P<0.05). The risk of death in the high PLR group was 3.889 times that of the low PLR group, and the risk of death in the high PNI group was 0.484 times that of the low PNI group. Conclusions Relapse has a significant impact on the prognosis of children with MB. For children with recurrent MB, high PNI was a protective factor, but high PLR is a risk factor for a poor prognosis.
Jingjing LIU , Lei LIU , Shuxu DU , Yanling SUN , Xiaojun GONG , Jin ZHANG , Wanshui WU , Liming SUN . The survival predictive value of pre-treatment blood test indicators and risk factors for children with recurrent medulloblastoma[J]. Journal of Clinical Pediatrics, 2024 , 42(6) : 538 -542 . DOI: 10.12372/jcp.2024.23e0613
[1] | Hill RM, Richardson S, Schwalbe EC, et al. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study[J]. Lancet Child Adolesc Health, 2020, 4(12): 865-874. |
[2] | Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study[J]. J Neurooncol, 2016, 129(3): 515-524. |
[3] | Aguilera D, Mazewski C, Fangusaro J, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience[J]. Childs Nerv Syst, 2013, 29(4): 589-596. |
[4] | Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery[J]. Am J Surg, 1980, 139(1): 160-167. |
[5] | Xu R, Chen XD, Ding Z. Perioperative nutrition management for gastric cancer[J]. Nutrition, 2022, 93: 111492. |
[6] | Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer[J]. Ann Surg, 2020, 271(4): 693-700. |
[7] | Fang KH, Chang SW, Lee YC, et al. Preoperative prognostic nutritional index predicts prognosis of patients with oral cavity cancer[J]. Oral Dis, 2022, 28(7): 1816-1830. |
[8] | Zhang H, Gao L, Zhang B, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis[J]. Sci Rep, 2016, 6: 22618. |
[9] | Pizer BL, Clifford SC. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials[J]. Br J Neurosurg, 2009, 23(4): 364-375. |
[10] | Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study[J]. J Neurooncol, 2016, 129(3): 515-524. |
[11] | Lim DH. Role of radiotherapy in patients with relapsed medulloblastoma[J]. Brain Tumor Res Treat, 2023, 11(1): 22-27. |
[12] | 孙艳玲, 刘晶晶, 杜淑旭, 等. 101 例儿童复发髓母细胞瘤的序贯治疗生存分析[J]. 中国当代儿科杂志, 2021, 23(2): 164-168. |
[13] | Liu D, Czigany Z, Heij LR, et al. The value of platelet-to-lymphocyte ratio as a prognostic marker in cholangiocarcinoma: a systematic review and meta-analysis[J]. Cancers (Basel), 2022, 14(2): 438. |
[14] | Li B, Zhou P, Liu Y, et al. Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis[J]. Clin Chim Acta, 2018, 483: 48-56. |
[15] | Kumarasamy C, Tiwary V, Sunil K, et al. Prognostic utility of platelet-lymphocyte ratio, neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in head and neck cancers: a detailed prisma compliant systematic review and meta-analysis[J]. Cancers (Basel), 2021, 13(16): 4166. |
[16] | Li K, Duan WC, Zhao HB, et al. Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with the prognosis of Group 3 and Group 4 medulloblastoma[J]. Sci Rep, 2019, 9(1): 13239. |
[17] | Tokunaga R, Sakamoto Y, Nakagawa S, et al. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection[J]. Int J Clin Oncol, 2017, 22(4): 740-748. |
[18] | 陈莉莉, 李鑫, 康晓慧, 等. 术前预后营养指数、中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值对脑胶质瘤患者术后预后的评估价值研究[J]. 现代生物医学进展, 2023, 23(5): 845-849. |
/
〈 |
|
〉 |